Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122129 | 0.95 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2TDP1TSHRENPP2 | |
| SCHEMBL18839942 | 0.93 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2TDP1ENPP2LPAR2 | |
| SCHEMBL3750987 | 0.93 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2TDP1ENPP2LPAR2 | |
| SCHEMBL123895 | 0.89 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2TDP1TSHRENPP2 | |
| SCHEMBL28034730 | 0.88 | TSHR (0.41) | ALDH1A1SMN1; SMN2TDP1TSHRMAPK1 | |
| SCHEMBL21327777 | 0.86 | TSHR (0.40) | ALDH1A1SMN1; SMN2TDP1TSHRMAPK1 | |
| SCHEMBL3888232 | 0.83 | TSHR (0.38) | ALDH1A1SMN1; SMN2TDP1TSHRMAPK1 | |
| SCHEMBL1411899 | 0.83 | TSHR (0.38) | ALDH1A1SMN1; SMN2TDP1TSHRMAPK1 | |
| SCHEMBL25211268 | 0.81 | TSHR (0.36) | ALDH1A1SMN1; SMN2TDP1TSHR | |
| SCHEMBL636117 | 0.81 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2TDP1TSHRENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084289-B1 | PROCESS FOR PRODUCING OF EPOXY-CONTAINING (METH)ACRYLIC ESTERS, USING LIPASES | BASF SE (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8183018-B2 | Process for producing of epoxy-containing (meth)acrylic esters, using lipases | BASF AKTIENGESELLSCHAFT (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20100048927-A1 | PROCESS FOR PRODUCING OF EPOXY-CONTAINING (METH) ACRYLIC ESTERS, USING LIPASES | BASF SE (DE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048927-A1 | PROCESS FOR PRODUCING OF EPOXY-CONTAINING (METH) ACRYLIC ESTERS, USING LIPASES | MGLL, ADH1A, CES2 | ALDH1A1 59/4885SMN1; SMN2 3990/4885TDP1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.